Market Cap 9.60B
Revenue (ttm) 88.04M
Net Income (ttm) -784.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -891.59%
Debt to Equity Ratio -0.35
Volume 1,579,200
Avg Vol 2,050,486
Day's Range N/A - N/A
Shares Out 124.43M
Stochastic %K 2%
Beta 0.42
Analysts Strong Sell
Price Target $106.95

Company Profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a pot...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 3000
Address:
350 Oyster Point Boulevard, South San Francisco, United States
timfris
timfris Jul. 31 at 4:32 PM
$CYTK these are the days you add, IMO.
0 · Reply
Merlintrader
Merlintrader Jul. 31 at 3:07 PM
Cytokinetics ($CYTK) Stock Hub 2026: MYQORZO, Aficamten and the Hypertrophic Cardiomyopathy Franchise Expansion https://www.merlintrader.com/cytokinetics-incorporated-stock-hub/
0 · Reply
SM07
SM07 Jul. 31 at 1:09 PM
$CYTK should be a target in $NVO radar, if and when the Danes get over their not invented here syndrome.
0 · Reply
LewisDaKat
LewisDaKat Jul. 30 at 5:00 PM
$CYTK Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO ? (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales https://marketwirenews.com/stock/cytk/news/cytokinetics-announces-mhra-marketing-authorisation--5063878169833850.html?utm_source=stocktwits
0 · Reply
Florestan
Florestan Jul. 25 at 1:19 PM
0 · Reply
biochirp
biochirp Jul. 22 at 5:50 PM
$CYTK 👀👀👀
0 · Reply
Quantumup
Quantumup Jul. 22 at 12:32 PM
Evercore ISI🏁 $TENX OP-$39 & says that it models a strong 50% PoS—sees upside ranging from +250% (base case data) to 10x (home-run data)—90% downside on failure. $TECX MRK $CYTK EWTX MLYS AZN TNYA Evercore ISI said -- "This is not a conviction call for us. There's not enough data for this to be a conviction call for anyone. That's why the stock is only $1B mkt cap in the context of massive potential upside driven by the huge unmet need in PH-HFpEF. But we spent a lot of time digging in and walked away thinking...this trial has a real shot at working. We model a strong 50% PoS, and see upside ranging from +250% (base case data) to 10x (home-run data) depending on the strength of data; 90% downside on failure. Scenarios below. We calculate that the current trading price implies only ~20 25% odds of LEVEL working. So if you believe TENX has around coin flip odds of this study working, you should find the current stock setup compelling. We're initiating coverage at Outperform with a $39 PT.
0 · Reply
Kobe2324
Kobe2324 Jul. 20 at 1:58 PM
$CYTK don’t listen to anyone on this page, you will lose your money. So many great companies to invest in
3 · Reply
SM07
SM07 Jul. 17 at 2:54 PM
$CYTK perfectly ripe for a sale to BP at a very juicy price.
1 · Reply
buddyopalosam
buddyopalosam Jul. 17 at 12:46 PM
$CYTK buyer at 75
0 · Reply
Latest News on CYTK
Cytokinetics announces MHRA authorization for Myqorzo

2026-07-30T10:25:52.000Z - 3 days ago

Cytokinetics announces MHRA authorization for Myqorzo


Cytokinetics upgraded to Buy from Neutral at UBS

2026-06-29T10:20:13.000Z - 4 weeks ago

Cytokinetics upgraded to Buy from Neutral at UBS


Cytokinetics price target raised to $118 from $100 at Mizuho

2026-06-24T11:06:08.000Z - 5 weeks ago

Cytokinetics price target raised to $118 from $100 at Mizuho


Cytokinetics launches Myqorzo in Germany

2026-06-01T14:24:49.000Z - 2 months ago

Cytokinetics launches Myqorzo in Germany


Cytokinetics to Participate in June Investor Conferences

May 27, 2026, 4:00 PM EDT - 2 months ago

Cytokinetics to Participate in June Investor Conferences


Cytokinetics Transcript: AGM 2026

May 27, 2026, 1:00 PM EDT - 2 months ago

Cytokinetics Transcript: AGM 2026


Cytokinetics Slides: Corporate presentation

May 27, 2026, 7:00 AM EDT - 2 months ago

Cytokinetics Slides: Corporate presentation


Cytokinetics to Hold Annual Meeting of Stockholders

May 20, 2026, 4:00 PM EDT - 2 months ago

Cytokinetics to Hold Annual Meeting of Stockholders


Cytokinetics Slides: Corporate presentation

May 19, 2026, 7:00 AM EDT - 2 months ago

Cytokinetics Slides: Corporate presentation


Cytokinetics initiated with a Buy, named a top pick at Citi

2026-05-18T20:22:58.000Z - 2 months ago

Cytokinetics initiated with a Buy, named a top pick at Citi


Cytokinetics price target raised to $97 from $92 at JPMorgan

2026-05-12T12:21:58.000Z - 2 months ago

Cytokinetics price target raised to $97 from $92 at JPMorgan


Cytokinetics 9.8M share Secondary priced at $71.00

2026-05-07T11:31:31.000Z - 3 months ago

Cytokinetics 9.8M share Secondary priced at $71.00


Cytokinetics price target raised to $108 from $98 at Stifel

2026-05-07T08:12:32.000Z - 3 months ago

Cytokinetics price target raised to $108 from $98 at Stifel


Cytokinetics Earnings Call Transcript: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cytokinetics Earnings Call Transcript: Q1 2026


Cytokinetics Quarterly report: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cytokinetics Quarterly report: Q1 2026


Cytokinetics Earnings release: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cytokinetics Earnings release: Q1 2026


Cytokinetics Slides: Q1 2026

May 5, 2026, 4:30 PM EDT - 3 months ago

Cytokinetics Slides: Q1 2026


Cytokinetics Announces Proposed Public Offering of Common Stock

May 5, 2026, 4:15 PM EDT - 3 months ago

Cytokinetics Announces Proposed Public Offering of Common Stock


Cytokinetics price target raised to $106 from $92 at Truist

2026-05-05T14:31:02.000Z - 3 months ago

Cytokinetics price target raised to $106 from $92 at Truist


Cytokinetics Transcript: Study result

May 5, 2026, 8:00 AM EDT - 3 months ago

Cytokinetics Transcript: Study result


Cytokinetics Press release: Study result

May 5, 2026, 8:00 AM EDT - 3 months ago

Cytokinetics Press release: Study result


Cytokinetics Slides: Study result

May 5, 2026, 8:00 AM EDT - 3 months ago

Cytokinetics Slides: Study result


Cytokinetics to Announce First Quarter Results on May 5, 2026

Apr 21, 2026, 4:00 PM EDT - 3 months ago

Cytokinetics to Announce First Quarter Results on May 5, 2026


Cytokinetics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Cytokinetics Proxy statement: Proxy filing


Cytokinetics Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 5 months ago

Cytokinetics Slides: Corporate presentation


Cytokinetics to Participate in March Investor Conferences

Mar 2, 2026, 4:00 PM EST - 5 months ago

Cytokinetics to Participate in March Investor Conferences


Cytokinetics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:30 PM EST - 5 months ago

Cytokinetics Earnings Call Transcript: Q4 2025


Cytokinetics Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 5 months ago

Cytokinetics Annual report: Q4 2025


Cytokinetics Earnings release: Q4 2025

Feb 24, 2026, 4:30 PM EST - 5 months ago

Cytokinetics Earnings release: Q4 2025


Cytokinetics Annual report: Q4 2025

Feb 24, 2026, 4:30 PM EST - 5 months ago

Cytokinetics Annual report: Q4 2025


Cytokinetics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 7 months ago

Cytokinetics Slides: Corporate presentation


Cytokinetics Transcript: FDA Announcement

Dec 19, 2025, 4:30 PM EST - 8 months ago

Cytokinetics Transcript: FDA Announcement


Cytokinetics Press release: FDA Announcement

Dec 19, 2025, 4:30 PM EST - 8 months ago

Cytokinetics Press release: FDA Announcement


US FDA approves Cytokinetics' heart disease drug

Dec 19, 2025, 4:08 PM EST - 8 months ago

US FDA approves Cytokinetics' heart disease drug


Cytokinetics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 11:20 AM EST - 9 months ago

Cytokinetics Transcript: Stifel 2025 Healthcare Conference


timfris
timfris Jul. 31 at 4:32 PM
$CYTK these are the days you add, IMO.
0 · Reply
Merlintrader
Merlintrader Jul. 31 at 3:07 PM
Cytokinetics ($CYTK) Stock Hub 2026: MYQORZO, Aficamten and the Hypertrophic Cardiomyopathy Franchise Expansion https://www.merlintrader.com/cytokinetics-incorporated-stock-hub/
0 · Reply
SM07
SM07 Jul. 31 at 1:09 PM
$CYTK should be a target in $NVO radar, if and when the Danes get over their not invented here syndrome.
0 · Reply
LewisDaKat
LewisDaKat Jul. 30 at 5:00 PM
$CYTK Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO ? (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales https://marketwirenews.com/stock/cytk/news/cytokinetics-announces-mhra-marketing-authorisation--5063878169833850.html?utm_source=stocktwits
0 · Reply
Florestan
Florestan Jul. 25 at 1:19 PM
0 · Reply
biochirp
biochirp Jul. 22 at 5:50 PM
$CYTK 👀👀👀
0 · Reply
Quantumup
Quantumup Jul. 22 at 12:32 PM
Evercore ISI🏁 $TENX OP-$39 & says that it models a strong 50% PoS—sees upside ranging from +250% (base case data) to 10x (home-run data)—90% downside on failure. $TECX MRK $CYTK EWTX MLYS AZN TNYA Evercore ISI said -- "This is not a conviction call for us. There's not enough data for this to be a conviction call for anyone. That's why the stock is only $1B mkt cap in the context of massive potential upside driven by the huge unmet need in PH-HFpEF. But we spent a lot of time digging in and walked away thinking...this trial has a real shot at working. We model a strong 50% PoS, and see upside ranging from +250% (base case data) to 10x (home-run data) depending on the strength of data; 90% downside on failure. Scenarios below. We calculate that the current trading price implies only ~20 25% odds of LEVEL working. So if you believe TENX has around coin flip odds of this study working, you should find the current stock setup compelling. We're initiating coverage at Outperform with a $39 PT.
0 · Reply
Kobe2324
Kobe2324 Jul. 20 at 1:58 PM
$CYTK don’t listen to anyone on this page, you will lose your money. So many great companies to invest in
3 · Reply
SM07
SM07 Jul. 17 at 2:54 PM
$CYTK perfectly ripe for a sale to BP at a very juicy price.
1 · Reply
buddyopalosam
buddyopalosam Jul. 17 at 12:46 PM
$CYTK buyer at 75
0 · Reply
Daniech0514
Daniech0514 Jul. 13 at 12:46 AM
$CYTK could this be the week we see high 90s or even 100? I hope so.
0 · Reply
Quantumup
Quantumup Jul. 9 at 12:06 PM
Oppenheimer🏁 $EWTX and said -- We are initiating coverage of Edgewise Therapeutics (EWTX) at Outperform, with a 12-18-month $51 price target. $CYTK $TENX BMY TECX Here's what else Oppenheimer had to say: https://x.com/Quantumup1/status/2075189602227298415?s=20
0 · Reply
Jack_Danielss
Jack_Danielss Jul. 7 at 6:05 PM
$CYTK Whole market getting crushed and this was up in a sea of red…strange trading…
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 4:55 PM
$CYTK Cytokinetics ($CYTK) Stock Hub 2026: MYQORZO, Aficamten And The Hypertrophic Cardiomyopathy Franchise Expansion https://www.merlintrader.com/cytokinetics-incorporated-stock-hub/
0 · Reply
SM07
SM07 Jul. 7 at 2:59 PM
$CYTK can be easily sold at $150+ ps
0 · Reply
BillionerOfKing
BillionerOfKing Jul. 7 at 1:50 AM
$CYTK Current Stock Price: $85.59 Contracts to trade: $85.0 CYTK Jul 17 2026 Call Entry: $2.80 Exit: $4.36 ROI: 56% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Quantumup
Quantumup Jul. 6 at 1:00 PM
Guggenheim⬆️ $EWTX's PT to $51 and reiterated at Buy. $CYTK $BMY TENX TECX Guggenheim said - We are updating our model following the planned sale of EWTX's muscular dystrophy business unit to Servier (private) for $1.55B upfront and up to $1.1B in regulatory / commercial milestones (expected to close in 3Q26), as well as the recent CIRRUS Part D data of EDG-7500 in oHCM and nHCM. '7500 delivered efficacy in line with CMIs or better, combined with a lack of dose-dependent impact on LVEF & no instances of LVEF <50% (see our takes HERE and HERE, as well as feedback from our KOL HERE). With EDG-7500 poised to be a serious competitor to CMIs in HCM, we are raising our PT to $51 from $41.
0 · Reply
Jack_Danielss
Jack_Danielss Jun. 30 at 8:21 PM
$CYTK any other longs here or is it just me and Blum
3 · Reply
Jack_Danielss
Jack_Danielss Jun. 30 at 4:11 PM
$CYTK all it needs a sniff of a buyout rumour and it’s gone…🔥🔥
0 · Reply
Jack_Danielss
Jack_Danielss Jun. 30 at 3:38 PM
$CYTK $VRNA vibes
0 · Reply
marygroovy
marygroovy Jun. 29 at 10:41 PM
$CYTK I’m ready to celebrate like the Tartan Army rolling into a Sox game. New 52-week highs, baby! No Cyto, no party✨✨✨
0 · Reply
SouthHaus
SouthHaus Jun. 29 at 8:16 PM
$CYTK Another all time high.
0 · Reply